Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671148 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
A Phase 3 study of Psoriatic Arthritis (PsA), sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
- 20
- Study locations
NCT03671148 is a Phase 3 study of Psoriatic Arthritis (PsA) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 444 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT03671148, a Phase 3 study of Psoriatic Arthritis (PsA), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Risankizumab
Study Locations (20)
Florida
- Arthritis & Rheumatic Disease Specialties /ID# 212582 - Aventura
- SIMED Health, LLC /ID# 207457 - Gainesville
- Sweet Hope Research Specialty Inc /ID# 168163 - Hialeah
- Rheum Assoc of Central FL /ID# 201629 - Orlando
- HMD Research LLC /ID# 208428 - Orlando
- Millennium Research /ID# 201627 - Ormond Beach
- Arthritis Center, Inc. /ID# 208116 - Palm Harbor
- IRIS Research and Development, LLC /ID# 166351 - Plantation
- BayCare Medical Group /ID# 201630 - St. Petersburg
- West Broward Rheumatology Associates /ID# 201234 - Tamarac
- University of South Florida /ID# 208467 - Tampa
California
- St. Jude Heritage /ID# 166842 - Fullerton
- Newport Huntington Medica /ID# 207423 - Huntington Beach
- Arthritis & Osteo Medical Ctr /ID# 166541 - La Palma
- East Bay Rheumatology Medical /ID# 166845 - San Leandro
- Inland Rheum Clin Trials Inc. /ID# 166621 - Upland
Connecticut
- New England Research Associates, LLC /ID# 166525 - Bridgeport
- Yale University /ID# 166330 - New Haven
Alabama
- Pinnacle Research Group /ID# 167953 - Anniston
Colorado
- Denver Arthritis Clinic /ID# 166442 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03671148
The ClinicalTrials.gov registry entry for NCT03671148 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis (PsA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03671148 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03671148 about?
NCT03671148 is a clinical study titled "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)". The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
What is the current status of trial NCT03671148?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2019-03-07. Estimated completion is 2026-06.
What conditions does trial NCT03671148 study?
This clinical trial studies the following conditions: Psoriatic Arthritis (PsA).
What interventions are being tested in trial NCT03671148?
The interventions under investigation include: Placebo (BIOLOGICAL), Risankizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03671148?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03671148 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis (PsA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.